There is an urgent need for new antibacterial drugs that are robust against the development of resistance. Drug repurposing is a cost-effective strategy to fast-track the drug development process. Here we examine why the nucleoside and nucleobase analogue drugs in particular present an attractive class for repurposing. Some of these drugs have already been evaluated for their potential as antibacterial agents. In addition to inhibiting bacterial growth and survival, some also act synergistically with antibiotics, and as such can enhance the therapeutic spectrum of currently available antibiotics. Furthermore, nucleoside and nucleobase analogue drugs can inhibit bacterial virulence and biofilm formation. Biofilms are known to impart antibiotic tolerance and are associated with chronic infections. Targeting biofilm formation thus renders pathogens more susceptible to antibiotic treatment and host immune defences. Moreover, specific analogues have properties that make them less susceptible to the development of resistance. Thus, nucleoside and nucleobase analogue drugs ought to be considered as new weapons in our fight against pathogenic bacteria.
Introduction
The discovery of antibiotics is without doubt one of the greatest medical achievements and proved to be a turning point in human history by saving countless lives and placing infectious diseases under control. However, there is a growing concern that we are approaching a post-antibiotic era in which common infections or minor injuries might become life threatening. 1 The widespread use of antibiotics in medicine, agriculture and other anthropogenic activities has been followed by the emergence and rapid dissemination of antibiotic-resistant pathogens. [2] [3] [4] Most worrisome, in clinical environments there are increasing reports of extensive drug-resistant infections. 5, 6 Indeed, the recent discovery of an Escherichia coli strain harbouring resistance genes to colistin and 14 other antibiotics on a plasmid is thought to herald the emergence of true pan-drug resistance. 7 It is estimated that 700000 people die of antibiotic-resistant infections every year, and that number is feared to increase to 10 million per year by 2050. 8 Aside from the tragic human cost, the economic impact of antibiotic resistance is enormous. The cost in terms of lost global production between now and 2050 is predicted to be US$100 trillion. 8 To continue our fight against pathogenic bacteria it is absolutely imperative that there should be no abatement in the quest for new antimicrobial agents. An emerging strategy is to repurpose drugs that are already approved for other uses. The antibiotic, antibiofilm and antivirulence activities of diverse drugs, including gallium compounds, alkylating agents, hormonal modulators and antimetabolites, were recently reviewed. [9] [10] [11] Here we will examine the striking antibacterial properties of nucleoside and nucleobase analogue drugs (NNADs). These drugs are important antiproliferative therapies used against cancer and viral diseases. Application of these NNADs for antibacterial therapy has, however, only been poorly evaluated, 12 We are of the opinion that these drugs could also have a significant impact on the clinical treatment of bacterial infections, with potentially a lower risk of resistance development, and that they could be a financially viable option for pharmaceutical companies. We argue that repurposing approved NNADs as bactericidal, bacteriostatic or antibiofilm agents could have the potential to circumvent important hurdles related to traditional antimicrobial discovery and illustrate this with recent experimental evidence. Finally, factors that need to be taken into account to assess the likelihood of resistance development against NNADs are discussed.
Nucleobase and nucleoside analogues have been in clinical use for several decades
Nucleotides are the basic structural units of DNA and RNA, and direct and control the production of proteins. Nucleotides serve as cofactors in a wide range of metabolic pathways including lipid and polyamine biosynthesis. Furthermore they function as energy carriers and are constituents of signalling molecules such as (p)ppGpp, cGMP and cAMP to name just a few. Because of this, NNADs that target enzymes of nucleotide metabolism constitute important elements of current anticancer and antiviral therapies. NNADs that are used for the treatment of cancer inhibit DNA V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
replication and repair while antiviral NNADs inhibit replication of the viral genome. 13 In addition, certain analogues can inhibit the enzymes that are involved in nucleotide biosynthesis and cause chain termination by depleting dNTP pools. There is also potential for other enzymatic cross-reactivity when analogues bind to regulatory sites where they cause activation or inhibition of enzymes. [14] [15] [16] Table 1 provides an overview of the 45 currently FDAapproved NNADs. Some NNADs have been in clinical use for over 50 years; however, these compounds are not routinely used against bacteria and only limited small-scale investigations into their antibacterial properties have been conducted.
Repurposing NNADs could overcome several hurdles in traditional antimicrobial discovery
Just like cancer cells and viruses, bacteria are fast-proliferating entities, 17 making them good candidate targets for drugs that interfere with DNA or RNA replication. Moreover, nucleotides and derived compounds have important functions as signalling molecules and cofactors in bacterial processes associated with biofilm formation, virulence and persistence, [18] [19] [20] [21] suggesting that NNADs might have other interesting activities against bacteria. Consistent with this, in recent years the bactericidal, antibiofilm or antivirulence activity of a subset of FDA-approved NNADs have been demonstrated, [22] [23] [24] [25] while other NNADs have been shown to enhance the efficacy of classic antimicrobials. [26] [27] [28] [29] However, the antibacterial effect of the majority of approved NNADs remains to be tested. Already reported activities against bacteria are listed in Table 1 and discussed in more detail in the following sections. Here we describe important hurdles associated with classical antimicrobial discovery and how repurposing of NNADs could overcome these.
(i) NNADs are synthetic compounds without prior evolutionary history in ecological settings
In ecological settings, natural antibiotics are thought to be 'weapons' that are used during microbial competition. 30 Antibiotic resistance mechanisms are considered to be akin to 'shields' that protect target organisms, or detoxifying systems that protect antibiotic producers from their own weapons. 31 Antibiotics may also have a role in intra-and inter-domain communication, where they can act as cues/coercions in complex microbial communities. 2, 32, 33 In this scenario, antibiotic resistance may serve as a mechanism to attenuate signal intensity. 2, 4, [33] [34] [35] [36] Regardless of their exact role in nature, it is now appreciated that resistance-conferring genes are the result of ancient evolution and not merely due to the modern pressures of anthropogenic antibiotic use. [37] [38] [39] [40] This is worrying, as the majority of antibiotic resistance mechanisms seen in clinical settings are acquired through horizontal gene transfer from taxonomically unrelated bacteria. [41] [42] [43] [44] Given the ecological importance of natural antibiotics and the presence of ancient resistance mechanisms it seems sensible to focus on identifying new, synthetic compounds, such as synthetically modified NNADs, that do not have a microbial origin. Because bacteria do not have an ancient history of exposure to synthetic antibiotics, resistance development is expected to be less prominent. However, it should be noted that efflux systems that have evolved to protect bacteria from diverse natural toxic small molecules in certain cases offer cross-protection against products of a synthetic origin. For example shortly after the introduction of fluoroquinolones into clinical practice in the 1980s, it became apparent that efflux systems provided Gram-negative bacteria with high levels of resistance. 45 Thus care should be taken since bacterial genomes, and mobile genetic elements, can harbour protection against toxic agents even without a requirement for past exposure.
(ii) NNADs have potential as antivirulence drugs, reducing the risk of resistance development Exposure to any compound that kills or inhibits growth of bacteria creates a strong selection pressure for resistance. 46 Even though resistance mechanisms are often costly to the bacterium in the absence of antibiotic, compensatory mutations that mitigate this cost rapidly spread so that the frequency of resistance does not decline when antibiotic use is reduced. 47 Instead of targeting growth, emerging strategies focus on targeting virulenceassociated phenotypes and/or behaviours that affect the susceptibility of pathogenic bacteria to the host's immune system or antibiotic treatment. 48, 49 It has been argued that targeting virulence without affecting bacterial growth, under certain circumstances, could generate much weaker selection for resistance than current antibiotics, while at the same time transforming pathogenic populations into a state that is less harmful to the host. [50] [51] [52] [53] As described below, certain NNADs have concentration ranges at which they inhibit the production of virulence factors without negative effects on growth. 22, 50, 54 (iii) Specific NNADs are expected to have activity against antibiotic-tolerant biofilms Most antibiotics have been developed to target free-living bacteria; however, it is now widely accepted that bacteria grow in multicellular communities that are encased in self-produced matrixes, called biofilms. 55 Biofilm-associated growth can enhance tolerance to antibiotics by 10-1000 times. [56] [57] [58] [59] To date there are no drugs in clinical use that were developed specifically to target biofilm formation. [60] [61] [62] Antibiofilm strategies can be directed at prevention of surface adhesion, colonization and matrix production by targeting specific cellular processes, as well as by interfering with quorum sensing. 63, 64 In vitro studies have shown that combining antibiofilm treatments with antibiotics can lower the tolerance of antibiotic-resistant pathogenic bacteria. 65, 66 Thus targeting biofilm formation is an attractive strategy that would render bacteria more vulnerable to host defences and enhance the therapeutic spectrum of currently available antibiotics. 48, 62, [67] [68] [69] Given the fact the major biofilm signalling molecule c-di-GMP is a nucleotide derivative, perturbations in the nucleotide pools due to the action of some NNADs are thought to cause reduced c-di-GMP levels and inhibition of biofilm formation. 23 (iv) The defined activity spectrum of NNADs could reduce microbiome disruption and resistance development NNAD-based prodrugs have potential to be activated in a speciesspecific manner by bacteria, and can therefore be used as speciesspecific antibiotics. 24 24, 70 have shown that bacterial deoxyribonucleoside kinases (dNKs) activate certain nucleoside prodrugs in a species-specific manner. The differences in susceptibility to these drugs were attributed to variations in the presence of kinase-encoding genes between the different taxonomic groups. 24 It would therefore be worthwhile to investigate whether other enzymes that are also involved in nucleotide metabolism (such as ribonucleotide reductases, thymidylate synthases, guanine deaminases and adenine deaminases) have species-specific interactions with nucleoside and nucleobase analogue drugs. The specific affinity that different bacterial species have towards the various analogue drugs could be exploited to design antibacterials that are effective against a narrow range of bacteria, which would be likely to reduce microbiome disruption and resistance development.
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(v) Repurposing of NNADs is less costly and time consuming than de novo drug discovery
In addition to the problem of antibiotic resistance and tolerance in the clinical environment, there has been a reduction in new antibiotic approvals over the past decades. 71 Other than the rapid emergence of resistance, factors that hamper antibiotic development include the high cost of de novo drug discovery and stringent regulatory requirements. The combination of these factors has contributed to the reluctance of pharmaceutical companies to invest in the development of new antimicrobials. 72, 73 Screening of already approved compounds to find those with desirable antibiotic, antibiofilm or antivirulence activities provides an interesting solution. This approach of drug repurposing takes less time than de novo drug discovery and is not associated with the same high costs and risks that typically accompany drug innovation. The drugrepurposing strategy has already been proven to be useful for identifying compounds with desirable antibacterial activities. Some of these drugs have been shown to alleviate infections in animal models, 9, 10, 74, 75 and specific drugs, such as 5-fluorouracil, are now being used in human clinical trials. 10 (vi) The safety profiles of NNADs are well established and risk factors associated with toxicity are known
Because the safety profiles of approved drugs have already been established, and potential side effects are already known, this information can be taken into account during drug-repurposing studies. When considering the approved uses of NNADs, their narrow therapeutic margins are incontestable. Most healthy adult cells are quiescent, and therefore targeting cancer cells with nucleoside analogues provides some level of selectivity. Nonetheless, certain tissues (such as hair follicles, bone marrow and intestinal epithelium) that are in a replicative state are vulnerable to the cytotoxic effects of NNADs. 76 Owing to their lower activity on mammalian enzymes, antiviral NNADs typically have better tolerance profiles than those used for treating cancer. 15 Nevertheless, long-term exposure to certain antiviral NNADs is associated with mitochondrial toxicity. 77 However, it is important to note that the mechanisms of toxicity for NNADs are selectivity/specificity problems. As such, toxicity is strongly dependent on dosage and intracellular concentration (as previously reviewed). 77 In addition, the duration of treatment is an important factor in cumulative toxicity. 78 The antibacterial effects of the various NNADs reviewed in the following sections occur at concentrations that are extremely low compared with those of their approved uses and treatment of bacterial infections is typically shorter than for chronic viral infections, chronic inflammatory diseases and cancer. Moreover, even though the cytotoxic effects of NNADs may have hindered their utilization as antibiotics in the past, we are now faced with the threat of increasing antibiotic resistance. In certain cases, the risks of minor cellular injury by cytotoxic agents might be lower than the risks associated with infections that do not respond to conventional antibiotics.
Examples of approved NNADs with activity against bacteria
Here we describe approved NNADs and summarize the recent advances that have been made in evaluating their potential as antibacterial agents or biofilm and virulence inhibitors. Special emphasis is placed on how the specific NNADs contribute to solving the antimicrobial discovery hurdles described above.
5-Fluorouracil
5-Fluorouracil is widely used in clinical settings as a systemic treatment for a variety of cancers as well as a topical treatment cancerous skin conditions. 5-Fluorouracil is a uracil analogue but contains a fluorine atom at the C-5 position instead of a hydrogen atom. 79 After entering the eukaryotic cell via the same facilitated transport mechanisms as uracil, 5-fluorouracil is converted into three main 80 The major activation product, FdUMP, is a suicide inhibitor of thymidylate synthase (TS). TS inhibition causes dTMP starvation, which is associated with perturbations in the levels of other deoxyribonucleotides and disrupted DNA synthesis and repair. 10, 80 Another 5-fluorouracil metabolite, FdUTP, causes point mutations when it is incorporated into DNA, as it base pairs with guanine instead of adenine. The combination of disrupted DNA repair and repeated nucleotide misincorporation ultimately results in DNA strand breaks and cell death. The third mode of 5-fluorouracil toxicity is due to the activation product FUTP which is incorporated into RNA. This negatively affects many aspects of RNA processing and function, including the formation of mature rRNA, the posttranscriptional modification of tRNA, and the assembly and activity of snRNA/protein complexes, as reviewed previously. 80 In bacteria, 5-fluorouracil is also converted to FdUMP, FdUTP and FUTP (see Figure 1 ) with similar mutagenic and cytotoxic outcomes as described for eukaryotic cells. The potent bactericidal effects of 5-fluorouracil against several bacterial pathogens was first established three decades ago. It was confirmed to inhibit the growth of Staphylococcus aureus and Staphylococcus epidermidis with an MIC 50 0.8 mg/L, and it was found to act synergistically with b-lactams against Gram-negative organisms. 81, 82 The fractional inhibitory concentration indexes (FICIs), where a FICI lower or higher than 1 indicates synergy or antagonism, respectively, of 5-fluorouracil and cefazolin, piperacillin and carbenicillin against E. coli were 0.61, 0.68 and 0.64, respectively. 82 More recently, it was found that 50 mg/L 5-fluorouracil acts synergistically with sub-MIC concentrations of tobramycin against S. aureus, leading to a .100-fold decrease in viable bacterial count after 3 h of treatment compared with treatment with sub-MIC tobramycin alone. Review JAC Some bacteria show deviations from the canonical reactions. For example, in Mycobacterium tuberculosis the most likely route for 5-fluorouracil metabolism would be through its conversion to FUMP which is further processed into FUTP and FdUTP, while other pathways are considered unlikely given the absence of the enzymes thymidine kinase (tdk), uridine phosphorylase (udp) and uridine kinase (udk). 83 Recent investigation into the antimycobacterial action of 5-fluorouracil revealed that 5-fluorouracil becomes incorporated into sugar nucleotides. Fluorinated versions of UDP-Gal, UDP-GlcNAc and UDP-MurNAc-pentapeptide were identified. 83 The presence of 5-fluorouracil in sugar nucleotides interferes with their role as activated sugar donors for the mycobacterial mycolyl arabinogalactan peptidoglycan complex production. These findings support earlier studies that provided evidence for inhibition of cell wall biosynthesis in E. coli and S. aureus by 5-fluorouracil. [84] [85] [86] Thus, in addition to DNA and RNA damage, 5-fluorouracil also exerts its bactericidal effect via the inhibition of cell wall biosynthesis. 83 The proposed pathway for 5-fluorouracil and 5-fluorocytosine metabolism in bacteria is summarized in Figure 1 .
The first evidence that 5-fluorouracil can inhibit biofilm formation by S. epidermidis was provided by Hussain et al. 87 More recent studies demonstrated that 5-fluorouracil inhibits biofilm formation and virulence in Pseudomonas aeruginosa 54 and enterohaemorrhagic E. coli. 22 The biofilm inhibitory effect of 5-fluorouracil is concentration dependent and influenced by the nutrient composition of the growth medium, with higher activity in lower-nutrient conditions. In nutrient-rich Lysogeny Broth medium, 3.25 mg/L 5-fluorouracil decreased P. aeruginosa PA14 biofilm formation by about 70% while the specific growth rate was only decreased by 20%, and 26.02 mg/L 5-fluorouracil inhibited biofilm production by more than 90% with a 50% reduction in the specific growth rate. In nutrient-poor M9 glucose medium, 1.3 mg/L 5-fluorouracil inhibited biofilm formation by 56% without affecting growth. The following quorum-sensing regulated virulence factors were also inhibited: LasB elastase activity, pyocyanin production, rhamnolipid production, swarming motility and quinolone signal production. At higher concentrations (3.25 mg/L 5-fluorouracil), biofilm formation was inhibited by 61%, but growth was also inhibited. 54 In E. coli 5-fluorouracil reduced biofilm formation 5-fold with about 42% toxicity at 3.25 mg/L. The antibiofilm activity of 5-fluorouracil relies on the presence of AriR (also known as YmgB), a regulatory protein which is upregulated in response to indole (see Figure 1) . The importance of indole in various bacterial processes including virulence induction, cell cycle regulation, acid resistance and biofilm formation is reviewed by Hu et al. 88 AriR, which is a repressor of biofilm formation, 89 was upregulated 3.7-fold in the presence of 1.3 mg/L 5-fluorouracil in LB medium. When 5-fluorouracil was added to an ariR deletion mutant, biofilm inhibition did not occur. 22 Studies conducted by our own research group indicate that 5-fluorouracil also has potential as an anti-Salmonella treatment. At concentrations of 1.3 mg/L, 5-fluorouracil causes near complete inhibition of planktonic and biofilm growth; however, at a concentration of 0.156 mg/L, biofilm formation is reduced by 80% without affecting planktonic growth (A. E. J. Yssel, J. Vanderleyden and H. P. Steenackers, unpublished data). Interestingly, AriR is not present in Salmonella and therefore 5-fluorouracil's mechanism of biofilm inhibition in this genus is probably different than in E. coli. Perhaps the most significant finding regarding the use of 5-fluorouracil as an antibacterial comes from large-scale randomized human trials, in which 5-fluorouracil was applied as a coating on central venous catheters. 90 The aforementioned study showed that the anti-infective properties of 5-fluorouracil exceeded that of silver sulfadiazine and chlorhexidine. 90 The approximate cumulative dose of 5-fluorouracil eluted over 28 days was 1 mg, which is below the lowest toxic dose in humans (6 mg/kg/3 days), which is associated with cardiac and respiratory side effects. 91 5-Fluorouracil was undetectable when plasma samples from goats implanted with a 5-fluorouracil-coated central venous catheter for a period of up to 21 days were analysed by means of liquid chromatography/ tandem mass spectrometry. Furthermore, histopathologic examination of the catheter/host tissue interface did not reveal any evidence of local tissue toxicity. Together these results strongly indicate that using 5-fluorouracil as an antibiofilm coating on medical implant devices would be safe. 90 
5-Fluorocytosine
5-Fluorocytosine is a synthetic antimycotic compound with the brand name Ancobon and is used for treating serious infections caused by Candida or Cryptococcus neoformans. 5-Fluorocytosine is a prodrug of 5-fluorouracil. 5-Fluorocytosine is not intrinsically toxic to fungi, but once taken up into susceptible fungal cells it is converted to 5-fluorouracil by cytosine deaminase. 92 Thereafter it is further metabolized to FUTP, FdUTP and FdUMP, leading to disturbed protein and DNA synthesis as described above (Figure 1) .
Imperi et al. 50 studied the effect of 5-fluorocytosine on P. aeruginosa pathogenicity. They found that 5-fluorocytosine did not affect P. aeruginosa growth (MIC .1291 mg/L). However, it had a very high inhibitory activity against pyoverdine production (IC 50 values of 0.3873 mg/L). In addition to pyoverdine inhibition, other critical virulence factors such as exotoxin A and protease PrpL were also inhibited. Using a mouse model of pulmonary infection they showed that an intraperitoneal dose of 30 mg/kg/day suppressed virulence without affecting the viability of the bacterial cells. 50 This dose is far below the mouse LD 50 of 1190 mg/kg and below the dosage range of 50-150 mg/kg/day recommended for humans. 93, 94 Although the exact molecular mechanism by which 5-fluorocytosine inhibits P. aeruginosa virulence factors is unknown, it was shown that 5-fluorocytosine toxicity relies on its metabolic conversion to 5-fluorouracil by cytosine deaminase (encoded by codA). Mammals and other higher eukaryotes do not have counterparts for cytosine deaminase, making 5-fluorocytosine an ideal drug for selectively targeting organisms capable of assimilating and activating the prodrug. 50 Aside from its low toxicity in humans, other clinically desirable characteristics of 5-fluorocytosine include its ready absorption after oral administration, high bioavailability and efficient penetration throughout the body. 92 Moreover, the dosing levels that are currently recommended for treating fungal infections lead to serum levels that are 40-fold higher than the levels needed to inhibit P. aeruginosa virulence. This suggests that typical doses are sufficiently potent for use in treating P. aeruginosa infection. 50 The in vitro and in vivo activity of 5-fluorouracil and 5-fluorocytosine against a variety of bacterial species paves the way for further clinical trials on the antivirulence and antibiofilm efficacy of these compounds in humans.
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5-Azacytidine
5-Azacytidine, an analogue of cytidine, is sold under the trade name Vidaza and mainly used in the treatment of myelodysplastic syndrome. It possesses cytotoxic, antineoplastic, abortive and mutagenic activity. 95 The cytotoxic effect of 5-azacytidine proceeds via two mechanisms: at low doses it interferes with gene regulation by inhibiting DNA methylation by methyl transferases (MTases), leading to inappropriate gene activation. 96 It is also an inhibitor of RNA methylation. 97 At higher doses its derivatives, 5-azacytidine triphosphate and 5-azadeoxycytidine triphosphate, get incorporated into RNA and DNA, respectively. 98 The hypomethylating effect of 5-azacytidine depends on the altered C-5 position. 99 Other cytidine analogues such as 6-azacytidine or gemcitabine do not have this property. In fact gemcitabine prevents demethylation of DNA, leading to hypermethylation, which also affects gene regulation and DNA repair. 100 The activated methyl cycle (AMC) is an important biosynthesis pathway that produces L-methionine for protein synthesis as well as S-adenosyl-L-methionine (SAM), the major methyl donor in the cell. When SAM donates its methyl group, it is converted to S-adenosyl-L-homocysteine (SAH). SAH can be recycled back to SAM via the AMC (Figure 2 ). In bacteria, the quorum-sensing molecule, AI-2, which is an important regulator of biofilm formation, 101 is formed as a by-product of the AMC. Because of the inhibitory effect of 5-azacytidine on DNA MTases and the involvement of MTases in the AMC, Yadav et al. 102 were interested in the effect of 5-azacytidine on AI-2 production and biofilm formation by Streptococcus pneumoniae. They found that the inhibitory effect of 5-azacytidine is higher for biofilm growth than for planktonic growth. At 24.42 mg/L 5-azacytidine, the degree of biofilm inhibition was nearly twice that of planktonic growth inhibition. Scanning electron microscopy revealed that 5-azacytidine disrupted biofilm organization, since the treated biofilms were thin, cells were scattered in clumps, and microcolonies were absent. Expression analysis of 11 genes involved in AI-2 synthesis, competence, and DNA repair and synthesis was conducted. Genes that were found to be downregulated by 5-azacytidine include luxS, metK, pfs and cmk. 102 The enzymes encoded by luxS and pfS are both involved AI-2 biosynthesis and detoxification of methylthioadenosine/S-adenosylhomocysteine (MTA/SAH), which are toxic byproducts of the AMC, and metK is involved in SAM production (Figure 2 ). Cytidylate kinase (encoded by cmk) catalyses the transfer of a phosphoryl group from ATP to CMP or dCMP; thus its downregulation would interfere with DNA synthesis. The authors indicated that it is unclear whether biofilm inhibition by 5-azacytidine is due to the downregulation of AI-2 production, changes in SAM levels or the accumulation of toxic by-products of the AMC. 102 Although insightful, the gene expression analysis of the study was limited to a small set of genes analysed with RTqPCR. Further comprehensive transcriptome analysis would likely yield additional insights into how interfering with the AMC affects S. pneumoniae biofilm growth and quorum sensing. Some compelling supplementary information was obtained in a very recent investigation into the effect of 5-azacytidine on the transcriptome of E. coli. Expression changes for 63 genes were observed, the majority of which were up-regulations. It was found that transcription was affected by two mechanisms, one involving loss of DNA methylation, and the other involving a DNA-damage response mechanism that is independent of methylation loss. 103 Because 5-azacytidine impacts the transcription of many genes, the possibility certainly exists that biofilm-related processes which are unrelated to AI-2 production and the AMC could be affected.
Further encouraging results were obtained with the non-FDAapproved compounds 1-(4-bromophenyl)-5-(2-furylmethylene)-3-phenyl-2-thioxodihydro-4,6(1 H,5 H)-pyrimidinedione (hereinafter simply referred to as pyrimidinedione) and sinefungin. Pyrimidinedione is a potent inhibitor of DNA adenine methyltransferase (DAM), an enzyme unique to bacteria. It was found that pyrimidinedione significantly inhibits pneumococcal biofilm growth at concentrations that are not cytotoxic to human epithelial cells. 104 Sinefungin, which is an experimental drug, is a structural analogue of SAM. Sinefungin reduces the production of AI-2, affecting cellto-cell connections and disrupting pneumococcal biofilm formation. 105 The results obtained with azacytidine, pyrimidinedione and sinefungin highlight the potential of interfering with biofilm formation and AI-2 production via disrupting the AMC, 105 and give strong support for testing other methyltransferases, such as decitabine, for the treatment of pneumococcal infections.
Azathioprine and 6-mercaptopurine
Azathioprine (brand name Imuran, originally developed as an anticancer drug) and its derivative 6-mercaptopurine (brand name Purinethol) are widely used immunosuppressive drugs for treatment of ulcerative colitis, Crohn's disease, myasthenia gravis, atopic dermatitis and intractable pruritus. [106] [107] [108] [109] [110] Studies published almost a decade ago revealed that azathioprine and 6-mercaptopurine inhibit the growth of Mycobacterium avium subspecies paratuberculosis (MAP), a bacterium that is associated with Crohn's disease. 111, 112 Interestingly, other rapidly growing mycobacteria, M. avium and Mycobacterium smegmatis, were resistant to azathioprine and 6-mercaptopurine. 112 Synergy between 6-mercaptopurine and the antibiotics azithromycin, clarithromycin, rifampicin, rifabutin and ethambutol has also been reported. 26 More recently it was demonstrated that azathioprine inhibits biosynthesis of c-di-GMP (a signal molecule that plays an important role in regulating biofilm formation) by interfering with intracellular nucleotide pool availability. Exposure to 25 mg/L azathioprine resulted in a 50% reduction of intracellular c-di-GMP levels in E. coli and prevented biofilm formation. In silico docking experiments suggested that azathioprine has high affinity for the cyclohydrolase domain of AICAR transformylase (a key enzyme in the purine biosynthesis pathway). Binding of azathioprine to AICAR transformylase might interfere with purine nucleotide biosynthesis by inhibiting the enzyme's activity. It is possible that even a slight reduction in GTP pools can negatively impact c-di-GMP synthesis by directing available GTP towards transcription and translation instead of signal molecule production. 23 c-di-GMP is ubiquitous in bacteria, where it regulates multiple cellular processes including motility, biofilm formation and virulence. 19, 20, [113] [114] [115] Thus, drugs that interfere with c-di-GMP signalling could have activity against diverse bacterial species.
Caffeine
Caffeine is a methylated xanthine analogue which is not only consumed in copious amounts by coffee lovers, but is also used to Review JAC prevent and treat bronchopulmonary dysplasia and apnoea in premature babies. 116, 117 Methylated xanthine analogues act as adenosine receptor antagonists in humans. 118 In bacteria, methylated xanthine analogues affect bacterial physiology by interfering with the following processes: (i) inhibition of thymidine uptake; (ii) inhibition of the conversion of thymidine to dTTP; (iii) inhibition of DNA synthesis and repair; (iv) reduction of RNA and protein synthesis; and (v) increase in cAMP levels due to inhibition of cAMP phosphodiesterase. [119] [120] [121] [122] [123] [124] The first evidence that caffeine can disrupt quorum sensing was presented in 2013 by Norizan et al. 125 They showed that 100-1000 mg/L caffeine inhibited short-chain acyl homoserine lactone (AHL) production by P. aeruginosa PA01 in a concentrationdependent manner with only trace amounts of AHLs produced at 1000 mg/L. The reduction in AHLs was not due to degradation by caffeine and the applied concentrations did not affect bacterial growth. The mechanism by which caffeine inhibits the synthesis of AHLs remains unsolved. Given the importance of AHLs in the regulation of virulence and biofilm formation, it could be interesting to investigate the anti-virulence or anti-biofilm properties of caffeine and other xanthine analogues, such as aminophylline and pentoxifylline.
Azidothymidine
Azidothymidine (also known as AZT or zidovudine) is an analogue of thymidine in which the 3 0 -hydroxy group is replaced with an azido group. Upon entry into an HIV-infected cell it is phosphorylated. The triphosphorylated form acts as an HIV reverse transcriptase inhibitor by inducing DNA chain termination due to the absence of the 3 0 -hydroxy group. 
Review
The antibacterial activity of azidothymidine was demonstrated three decades ago. 126, 127 It was shown that the antibacterial activity relies on the presence of a thymidine kinase with the ability to phosphorylate azidothymidine. Azidothymidine is active against Gram-negative bacteria while it has no effect on Gram-positive bacteria. Recent research by Sandrini et al. 24 provided strong evidence that species-specific activation of azidothymidine by bacterial thymidine kinases is important for the drug's selective activity. A comprehensive investigation by Doléans-Jordheim et al. 128 into the mechanism of azidothymidine's effect against several bacterial species showed that it is particularly active against enterobacteria. These results are in agreement with observations that HIV-positive patients treated with azidothymidine are less likely to develop Salmonella infections. 25 It was demonstrated that azidothymidine acts in synergy with aminoglycosides. The most effective combination is with gentamicin (mean FIC value of 0.40). With regards to side effects, azidothymidine is quite well tolerated in an anti-HIV setting; however, the effective doses for treating bacterial infection remain to be established. 128 
Gemcitabine
Gemcitabine is a prodrug used for the treatment of various cancers. It is an analogue of deoxycytidine in which the hydrogen atoms on the 2 0 carbon are replaced by fluorine. When transported into the human cell, it is activated by deoxycytidine kinase. Both gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP) inhibit processes required for DNA synthesis. Incorporation of dFdCTP instead of dCTP into DNA is thought to be the major mechanism by which cell death is induced. Following incorporation of dFdCTP on the end of the elongating DNA strand, one more deoxynucleotide is added and, thereafter, the DNA polymerases are unable to proceed. Proofreading enzymes are unable to remove gemcitabine from this position. Furthermore, the unique actions that gemcitabine metabolites exert on cellular regulatory processes serve to enhance the overall inhibitory activities on cell growth. 129 The activity of gemcitabine against bacteria was recently investigated by Sandrini et al. 24, 70 It was found that gemcitabine is active against Gram-positive bacteria and inactive against Gramnegative bacteria. Although the exact mechanisms of action of gemcitabine in bacteria are not yet clearly understood, the enzyme deoxyadenosine kinase was shown to be responsible for species-specific activation of the drug. 24, 70 Adult mice that were infected intraperitoneally with lethal doses of Streptococcus pyogenes (a b-haemolytic bacterium) did not develop systemic infection if they received 100 lg gemcitabine after infection. It was determined that exponential growth is a prerequisite for the efficacy of gemcitabine and that the stationary phase profoundly diminishes the susceptibility of bacterial cells. In vitro concentrations that can effectively kill S. aureus and S. pyogenes, are 0.002 and 0.2 mg/L respectively. 70 This is a clinically achievable range which is much lower than the plasma concentrations (2.99-5.99 mg/L) produced by the standard treatment dose for acute leukaemia, 130 with potentially lower side effects. Jordheim et al. 27 performed preclinical investigation into the antibacterial activity against MRSA strains and the association with gentamicin. Their experiments showed that gemcitabine and gentamicin act synergistically. Their results provide strong support for the use of nucleoside analogues in hospital settings, where multidrug-resistant nosocomial infections are increasingly problematic. Implant-associated osteomyelitis caused by S. aureus is a significant complication for orthopaedic patients following surgery. Given that the number of total hip and knee replacements is projected to grow significantly by 2030 in the United States alone, 131 we propose that gemcitabine be added to gentamicinimpregnated cement spacers to reduce complications associated with infection.
Resistance development against NNADs
When bacteria are exposed to agents that kill them or inhibit their growth there is a positive selection of bacteria that have acquired resistance mechanisms. Both strategies that reduce acquisition of resistance mechanisms or that reduce positive selection pressure on resistant strains are expected to result in lower resistance development.
Reduced acquisition of resistance can be achieved when multiple genes determine the structures of the molecular targets. In this case multiple mutations are required to offer high-level resistance, reducing the likelihood of high-level endogenous resistance. 132 If a resistance mechanism were to arise, the trade-off between the cost and benefit of resistance is an important factor in determining whether resistance becomes established. 47 Emerging strategies aim to circumvent the spread of resistance by not directly targeting growth but rather targeting virulence-or biofilm-related factors (so-called antivirulence drugs). Key predictions on the direction of selective pressure on strains resistant to antivirulence drugs are discussed in an opinion paper by Allen et al. 53 It is hypothesized that antivirulence drugs will generate weaker selection for resistance or even select against resistance under the following circumstances: (i) the targeted factor confers no benefit to the pathogen at the site of treatment; (ii) the targeted factor confers collective benefits to a well-mixed population; (iii) the targeted factor is conditionally beneficial and/or conditionally expressed; and (iv) the drug reduces the supply of quorum-sensing signals in a well-mixed population. 53 In the following paragraphs we argue that, based on the above criteria, NNADs may have properties which make them less susceptible to the development of resistance:
(i) NNADs can have multiple targets within the bacterial cell
Nucleotides have a multitude of roles within the bacterial cell and interact with many enzymes. NNADs (or their activation products) may thus have multiple enzymatic targets with which they can potentially cross-react to disrupt cellular functioning. As such, they could be more robust against acquisition of resistance mechanisms and resistance development. Although there are potential sources for endogenous resistance, as is discussed below, the use of drug combinations with diverse targets could reduce the likelihood of its emergence.
(ii) Combining treatment with antibiotics can prevent the establishment of resistance against NNADs Combination therapy is a widely used strategy to combat the emergence of resistance not only in bacteria, but also during Review JAC treatment of HIV and cancer. Combination therapies that have multiple molecular targets would require multiple mutations to achieve resistance. Synergistic combinations can also reduce the evolution of resistance by clearing the infection faster so that resistance mutations have less time to arise in the population. However, if resistance to one drug provides collateral resistance to the other drug, the combination will not be very effective in preventing the evolution of resistance. In the case of enteric bacterial resistance against azidothymidine, resistance was conferred by changes in the thymidine kinase enzyme, and no cross-protection against other antibiotics was observed. Combination with gentamicin therefore completely prevented regrowth of azidothymidine-resistant bacteria. 128 The framework provided by Munck et al. 133 for aiding the rational selection of antibiotic combinations that limit resistance evolution can be applied to NNADs to reveal suitable combinations with antibiotics.
(iii) Mutations providing resistance to NNADs are potentially disadvantageous
Endogenous resistance mechanisms against NNADs can occur, amongst others, by alteration of enzyme activity or uptake mechanisms. For example, several NNAD prodrugs are activated by nucleotide salvage enzymes, and these enzymes have been implicated in resistance devolpment. 24, 126, 128, 134 However, mutations in nucleotide salvage pathways may become quite costly under conditions where salvage is required. In addition to inactivation of salvage pathways, increased activity of analogue-degrading enzymes or reduced nucleoside uptake could also reduce susceptibility but may negatively affect the fitness or competitive ability of mutants by causing imbalances in the pools of pathway intermediates or by placing more strain on the de novo pathways. 24 (iv) NNADs can inhibit virulence and/or biofilm formation without impacting in vitro growth Several drugs discussed in this work have concentration ranges in which they affect quorum sensing, virulence and/or biofilm formation without impacting in vitro growth. According to Allen et al., 53 a good understanding of the in vivo fitness benefits and costs of the affected virulence factors and their group-beneficial character is required to evaluate the potential for resistance development. Pyoverdine, for example, which is targeted by 5-fluorocytosine, is a well-known group-beneficial virulence trait; 135 therefore it is expected that there will be selection against resistance. Indeed, resistant cells are expected to share the advantage of resistance, i.e. access to pyoverdine, with surrounding susceptible cells, but not the production cost, resulting in inferior performance of resistant cells. Sinefungin and 5-azacytidine, on the other hand, inhibit AI-2 production, while caffeine inhibits AHL production. These substances are thus quorum-sensing signal supply inhibitors. Selection is expected to be neutral because susceptible and resistant cells will likely equally sense and respond to signals produced by resistant strains, and thus experience the same benefits and costs.
Conclusion
On average, it takes about 15 years from discovery before a drug becomes available for clinical use, and only a small fraction of identified novel molecules pass the clinical trial phases. 136 Since 1962 only two new classes of antibiotics have made it onto the market. 137 Given the high attrition rates of pharmaceutical development, repurposing may be the only feasible approach to treat recalcitrant bacterial infections in the near future.
Although efforts to utilize NNADs for the inhibition of bacterial growth, virulence and biofilm formation are relatively new, we have described here some feasible candidates with promising in vitro (and in some cases in vivo) activities. The antibacterial actions of the drugs that we have discussed are diverse and range from interfering with methylation activity, inhibiting c-di-GMP biosynthesis by disturbing nucleotide pool concentrations, to interfering with quorum signalling. More extensive searches will likely continue to yield new, promising drugs that target a variety of processes. Differences between target enzymes in bacteria and mammals can be taken into account during the selection process in order to single out specific inhibitors with low host-toxicity. Egeblad et al.
14 have developed an approach for identifying interactions between NNADs and human enzymes involved in nucleotide metabolism. A thermal shift assay based on light scattering was used to measure enzyme-ligand binding between the purified enzymes and 45 FDA-approved NNADs. To facilitate the identification of NNADs that act selectively against bacteria or specific groups of bacteria, the protocol developed by Egeblad et al. could be modified to include bacterial enzymes. Moreover, the family of NNADs is expected to grow with the anticipated approval of additional drugs in the near future. A review by Jordheim et al. 15 focused on 53 such new compounds which are in various phases of development. The new agents are expected to have reduced long-term toxicity, amongst other improved properties.
Following the identification of compounds with promising antibacterial properties, their potential therapeutic applications need to be considered. Topically applied NNADs can, for example, be used to treat infected skin ulcers or burn-wounds, while intravenously administered NNADs can be useful against systemic infections. Because pharmacokinetics, pharmacodynamics, safety and adverse effects have already been determined, certain steps in the drug development path can be skipped. Typically, drug repurposing reduces the drug development process by 5 or more years. 138 In order to facilitate the repurposing of NNADs as antibacterial agents it is vital to move from small-scale in vitro studies to in vivo proof-of-concept experiments and finally Phase II and III clinical trials. Given that various animal models for studying a wide variety of bacterial infections are already established, [139] [140] [141] [142] preclinical tests ought to be relatively straightforward. The most progress towards clinical implementation of NNADs as antibacterial agents has been made with 5-fluorouracil. Indeed, catheters coated with 5-fluorouracil have been shown to prevent implantassociated biofilm formation in human trials, 90 and Angiotech has received FDA approval to manufacture them commercially in 2008. 143 We hope that this short review will encourage others to evaluate as yet untested NNADs for their potential as antibacterial compounds, either on their own or in combination with antibiotics that are currently on the market. Furthermore we hope that (pre)clinical investigations aimed at verifying the efficacy of these compounds will become a priority. 
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